Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls

Loss of HER2 in previously HER2-positive breast tumors is not rare, occurring in up to 50% of breast cancers; however, clinical research and practice underestimate this issue. Many studies have reported the loss of HER2 after neoadjuvant therapy and at metastatic relapse and identified clinicopathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Morganti, Stefania, Ivanova, Mariia, Ferraro, Emanuela, Ascione, Liliana, Vivanet, Grazia, Bonizzi, Giuseppina, Curigliano, Giuseppe, Fusco, Nicola, Criscitiello, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771738/
https://www.ncbi.nlm.nih.gov/pubmed/36627895
http://dx.doi.org/10.20517/cdr.2022.55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771738/
https://www.ncbi.nlm.nih.gov/pubmed/36627895
http://dx.doi.org/10.20517/cdr.2022.55

Ejemplares similares